Akero Therapeutics: Good Candidate For The MASH Basket
Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...
Model can predict, stratify liver cancer risk in noncirrhotic chronic hepatitis B
A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...
Too Old to Operate3 天
Model Can Predict, Stratify Liver Cancer Risk in Noncirrhotic Chronic Hep B
A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...
The EMBO Journal8 天
Multiomics reveals microbial metabolites as key actors in intestinal fibrosis in Crohn’s ...
The gut microbiota and its functional metabolites play crucial roles in the development of intestinal fibrosis in patients ...
Too Old to Operate9 天
Costly Comorbidities Persist for the 90% of Patients With MASH and No Cirrhosis
MASH's economic burden is substantial, particularly for patients with MASH and multiple comorbidities, even in the absence of ...